Compound versions of weight loss drugs will no longer be available, FDA rules
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...
Stellantis, Tesla, Viking Therapeutics: Market Minute
On today's Market Minute, Madison Mills examines the stories moving markets on Tuesday. Stellantis (STLA) shares are under ...
The State of Weight Loss Drugs
In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...
Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Weight-loss drug battle: Who are the latest players involved
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) diving into the opportunity to make effective and targeted ...
Novo Nordisk to slash weight-loss drug Wegovy prices
Mounting competition in the sector and rising obesity have led the pharmaceutical company to start selling the drug directly ...
Wegovy Gets Cheaper! Novo Nordisk Takes on Eli Lilly as Obesity Drug Battle Heats Up
Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...